J. Kevin Buchi, Chief Executive Officer

Mr. Buchi is currently the chairman of the board of directors at Dicerna Pharmaceuticals and a director of Amneal Pharmaceuticals and Benitec Biopharma Ltd. Mr. Buchi was most recently president and chief executive officer at TetraLogic Pharmaceuticals from 2012 to 2016. Previously, he served as Impax Laboratories' interim President and chief executive officer from December 2016 to March 2017. Earlier, he served as corporate vice president of Global Branded Products at Teva Pharmaceutical from 2011 to May 2012. Mr. Buchi also served as chief executive officer of Cephalon, which was acquired by Teva in October 2011. He had been at the company since 1991. Mr. Buchi holds a Masters of Management degree from the J.L. Kellogg Graduate School of Management from Northwestern University and a B.A. in Chemistry from Cornell University.

Patrick Hutchison, Chief Financial Officer

Mr. Hutchison most recently served as the Chief Financial Officer of SwanBio Therapeutics, a private gene therapy biotech company. Before SwanBio, Mr. Hutchison served as the Chief Financial Officer of Innocoll, Inc., a private biotech company. Prior to that, Mr. Hutchison served as the Chief Financial Officer of TetraLogic Pharmaceuticals, a public biotech company, and was formerly Vice President – Finance before assuming his role as CFO. Before that, Mr. Hutchison was Teleflex, Inc.’s Vice President – Corporate Controller and Chief Accounting Officer. Before his time at Teleflex, Mr. Hutchison was Vice President – Group Controller of Cephalon, Inc., an international biopharmaceutical company. Mr. Hutchison received his B.S. degree in Accounting from the Wharton School of the University of Pennsylvania (UPenn) and also earned a B.A. degree in Psychology from UPenn.

Dr. Lesley Russell, Chief Medical Officer

Dr. Russell previously served as Chief Medical Officer of Innocoll Holdings plc, a public pharmaceutical company. Prior to Innocoll, Dr. Russell served as Chief Operating Officer of TetraLogic Pharmaceuticals, Inc., a public biopharmaceuticals company. Prior to TetraLogic, she was Senior Vice President and Global Head of Research and Development for Global Branded Products at Teva Pharmaceuticals, Inc., a public pharmaceutical company. Dr. Russell was appointed to such role upon Teva's acquisition of Cephalon Inc., a public pharmaceutical company, where she served as Executive Vice President and Chief Medical Officer. She joined Cephalon as Vice President, Worldwide Clinical Research. Prior to Cephalon, Dr. Russell served as Vice President, Clinical Research at US Bioscience Inc., a public pharmaceutical company, and held positions of increasing responsibility within US Bioscience Inc. Dr. Russell was a clinical research physician at Eli Lilly U.K. and a Medical Director at Amgen U.K. Dr. Russell has served on the Board of Directors of Enanta Pharmaceuticals, Inc., a public biotechnology company, since November 2016, where she is also a member of its Audit Committee and Nominating and Governance Committee. Dr. Russell serves on the Board of Directors of Sojournix, Inc., a privately held US biotechnology company since 2018, where she is also a member of its Nominating and Governance Committee. Dr. Russell also serves on the Board of Directors of Imugene Limited, a public Australian biotechnology company, where she has been a director since April 2019. Dr. Russell was trained in Hematology/Oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children, Edinburgh. She received an MB.Ch.B. from the University of Edinburgh, Scotland and is a member of the Royal College of Physicians, United Kingdom. Dr. Russell is registered with the General Medical Council, United Kingdom.

Richard L. Sherman, J.D. , Chief of Staff

Mr. Sherman maintains an active worldwide legal and strategic business consulting practice focused on life sciences companies. He has served as general counsel for private and public development stage pharmaceutical and biotechnology companies for over 45 years, including Marinus Pharmaceuticals, Inc., TetraLogic Pharmaceuticals Corporation, Actinium Pharmaceuticals, Inc. and Hawaii Biotech, Inc. He spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the law firm of Pepper Hamilton LLP (1990-1992), and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group in New York. He has been a venture partner in SCP Private Equity Partners, SCP Vitalife Partners, and CIP Capital LP, investment firms with a focus on development stage life science and technology companies. Mr. Sherman has served on the board of directors of a number of public and private for-profit companies in the United States and Canada, including Biophage, Inc. (Chair), CytoMed, Inc., Functional Technologies Corp. (Chair), IBAH, Inc., Kenna Technologies, Inc., Leversense LLC, Mera Pharmaceuticals, Inc., Sparta Pharmaceuticals, Inc., Immunomedics, Inc., Hawaii Biotech, Inc., and PONTiS Orthopaedics LLC., as well as many non-profits, including The Sbarro Health Research Organization, Aloha Medical Mission, American Music Theater Festival (Chair) and SCA, Inc. (Chair). Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor in 1971.